Published by
@ShahidNShah
@ShahidNShah
May 16 to May 18, 2023
Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States
Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.
Returning to Boston, the timely 2nd Annual ALS Drug Development Summit is the only industry-focused conference dedicated to overcoming preclinical and clinical challenges currently facing ALS pipelines. This is your must-attend meeting showcasing the latest breakthroughs in ALS in 2022 and 2023.
Continue reading at als-drug-development.com
May 17 to May 20, 2023
COEX, 513 Yeongdong-daero, Gangnam-gu, Seoul, 06164, Korea (South)
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 20, 2024 at 12:59pm